Can Fite Biofarma (Can Fite Biofarma) Change In Inventory : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma Change In Inventory?

Can Fite Biofarma's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Can Fite Biofarma's inventory stayed the same from Sep. 2023 to Dec. 2023 .

Can Fite Biofarma's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Can Fite Biofarma's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Can Fite Biofarma's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Can Fite Biofarma's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.

Can Fite Biofarma Change In Inventory Historical Data

The historical data trend for Can Fite Biofarma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Change In Inventory Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Can Fite Biofarma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Can Fite Biofarma (AMEX:CANF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Can Fite Biofarma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Can Fite Biofarma's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Can Fite Biofarma's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.155
	=	0.00

Can Fite Biofarma Change In Inventory Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).